Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells 151,300 Shares of Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CEO Sanj Patel sold 151,300 shares of the stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $94.71, for a total transaction of $14,329,623.00. Following the transaction, the chief executive officer directly owned 774,500 shares in the company, valued at approximately $73,352,895. The trade was a 16.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Stock Performance

Shares of KNSA stock traded up $5.52 on Friday, reaching $93.86. 627,284 shares of the company were exchanged, compared to its average volume of 707,415. Kiniksa Pharmaceuticals International, plc has a 1 year low of $37.02 and a 1 year high of $98.48. The business has a 50-day moving average price of $80.18 and a 200 day moving average price of $61.10. The company has a market cap of $7.32 billion, a price-to-earnings ratio of 72.20 and a beta of 0.07.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. The firm had revenue of $285.97 million for the quarter, compared to analyst estimates of $260.66 million. As a group, equities analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.30 earnings per share for the current year.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Large investors have recently made changes to their positions in the stock. Allworth Financial LP grew its stake in shares of Kiniksa Pharmaceuticals International by 42.0% in the 2nd quarter. Allworth Financial LP now owns 453 shares of the company’s stock valued at $29,000 after buying an additional 134 shares during the period. Curry Webb Wealth Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International during the 3rd quarter worth approximately $29,000. KBC Group NV purchased a new stake in shares of Kiniksa Pharmaceuticals International during the 1st quarter valued at approximately $34,000. Nykredit A S purchased a new stake in shares of Kiniksa Pharmaceuticals International during the 2nd quarter valued at approximately $34,000. Finally, Jacobi Capital Management LLC purchased a new stake in shares of Kiniksa Pharmaceuticals International during the 3rd quarter valued at approximately $48,000. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently commented on KNSA. Zacks Research cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 30th. Wedbush lifted their target price on shares of Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 28th. Canaccord Genuity Group upped their target price on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Wells Fargo & Company increased their target price on shares of Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, October 28th. Finally, Weiss Ratings downgraded shares of Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c-)” rating in a research note on Wednesday, October 28th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $100.57.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.